Drugs / Biocon Insulin 70/30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04022291 | Jun 2019 → Jan 2020 | — | Biocon Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biocon Insulin 70/30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04022291 ↗ |
| Modality | Protein / enzyme biologic | “premixed suspension of human insulin” NCT04022291 ↗ |
| Route | Subcutaneous | “0.4 IU/kg Dose per administration, Subcutaneous Route of administration” NCT04022291 ↗ |